Patent ID: 11919957
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The method of claim 2, wherein
(a) the anti-CTLA-4 antibody is administered at a dose ranging from at least about 0.1 mg/kg to at least about 10.0 mg/kg body weight once about every 1, 2, 3, or 4 weeks
(b) the anti-PD-1 antibody is administered:
(i) at a weight based dose of 3 mg/kg body weight once every 2 weeks;
(ii) at a weight based dose of 5 mg/kg body weight once every 3 weeks;
(iii) at a weight based dose of 10 mg/kg body weight once every 3 weeks;
(iv) at a flat dose of about 240 mg once every 2 weeks;
(v) at a flat dose of about 360 mg once every 3 weeks; or
(vi) at a flat dose of about 480 mg once every 4 weeks; or

(c) any combination of (a) and (b).